<?xml version="1.0" encoding="UTF-8"?>
<p>This immunomodulator may be used in a subgroup of patients with severe forms of COVID-19 in that there is excessive activation of inflammation (“cytokine storm”). Identifying patients who would benefit from taking tocilizumab can be based on parameters such as growth ferritin levels, decreased platelet count, and increased ESR and C-reactive protein (
 <xref rid="B61" ref-type="bibr">61</xref>).
</p>
